Lianxin Zhou
Nanjing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Dexamethasone activates anti-tumor immunity in multiple myeloma by dismantling the GR-PPP1CB complex to restore STING/IRF3 signaling.
Journal: Journal for immunotherapy of cancer
Published: June 08, 2026
Targeting AVEN Liquid-Liquid Phase Separation in Colorectal Cancer: Insights From a Raddeanin A-Based Chemical Probe.
Journal: Basic & clinical pharmacology & toxicology
Published: March 31, 2026
NAT10-Mediated ac4C Modification of circANKRD12 Reprograms the Tumor Microenvironment.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: January 30, 2026
GART promotes multiple myeloma malignancy via tumor stemness mediated by activating the HSP90α/CDK6/β-catenin axis.
Journal: European journal of pharmacology
Published: November 22, 2024
Bruceine A Inhibits Cell Proliferation by Targeting the USP13/PARP1 Signalling Pathway in Multiple Myeloma.
Journal: Basic & clinical pharmacology & toxicology
Published: November 18, 2024
Extracellular vesicle-mediated delivery of circp53 suppresses the progression of multiple cancers by activating the CypD/TRAP/HSP90 pathway.
Journal: Experimental & molecular medicine
Published: November 10, 2024
LTe2 induces cell apoptosis in multiple myeloma by suppressing AKT phosphorylation at Thr308 and Ser473.
Journal: Frontiers in oncology
Published: July 30, 2023
Showing 1-9 of 9
Last Updated: 09/26/2026